Whether it's thanks to a winning business model or timely good news, some companies are taking the bear market in stride, and some are even crushing it.

In particular, there are three big pharma stocks that are rising higher amid the market's decline. If you're interested in building some all-weather growth into your portfolio, they might be right up your alley, so here's a quick rundown of each. 

Compared to the broader market's slump of around 5% in the last 12 months, AstraZeneca's (NASDAQ: AZN) stock has climbed 19%, making it a robust outperformer, to say the least. The company's success during the bear market is simply a matter of the strength of its drug development pipeline; with 184 projects in clinical trials and late-preclinical testing, it's among the largest in the world. In the last month alone, it bagged no fewer than three regulatory OKs in the E.U. and one in the U.S., and it also has 17 late-stage programs for new molecular entities. That means AstraZeneca has a very solid chance of commercializing a handful of new medicines for which there is no prior approval for any indication, likely making a lot of money in the process. 

Continue reading

Source Fool.com